01:04 , Jun 11, 2019 |  BC Extra  |  Company News

Why Brii Bio partnered with microbiome start-up Artizan

In its latest move to bring innovation to infectious diseases in China, Brii Bio has partnered with microbiome start-up Artizan, which is approaching IBD as if it were an infectious disease. Artizan Biosciences Inc. (New...
06:04 , Jun 10, 2019 |  BC Extra  |  Company News

With industry's growing kidney momentum, Everest begins building kidney portfolio

Everest Medicines added its first therapy to a planned renal portfolio on Monday through a deal with Calliditas. The therapy, Nefecon (PL-56, Nefigan), is in the Phase III Nefigard trial to treat IgA nephropathy. It...
21:46 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

Ethoxyindole-based CFB inhibitor for complement-mediated diseases

DISEASE CATEGORY: Renal; hematology; autoimmune disease INDICATION: Renal; nephropathy; paroxysmal nocturnal hemoglobinuria (PNH); arthritis In vitro , cell culture, mouse and rat studies identified an ethoxyindole-based CFB inhibitor that could help treat the complement-mediated diseases...
00:28 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Galderma planning Phase III program for atopic dermatitis therapy

Galderma said nemolizumab met the primary endpoint in a Phase IIb trial to treat adults with moderate-to-severe atopic dermatitis not adequately controlled by topical corticosteroids. The company plans to start a Phase III program of...
05:22 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

Olumiant meets Phase III endpoints for atopic dermatitis

Eli Lilly and Co. (NYSE:LLY) and Incyte Corp. (NASDAQ:INCY) said Olumiant baricitinib met the primary endpoints of the Phase III BREEZE-AD1 and BREEZE-AD2 trials to treat moderate to severe atopic dermatitis. In the double-blind, international...
19:38 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest adoptive transfer, or promoting the survival, of IgA-positive plasmablasts and plasma cells could help treat MS. In fecal samples from relapsing-remitting MS (RRMS) patients, counts...
19:37 , Jan 16, 2019 |  BC Innovations  |  Translation in Brief

Promoting gut plasmablasts for MS

Researchers from the University of Toronto and colleagues have linked the gut-brain axis to multiple sclerosis by showing gut plasmablasts and plasma cells suppress CNS inflammation during active MS, and suggested therapies that promote the...
21:19 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Tremfya superior to Cosentyx in head-to-head Phase III trial

Janssen Biotech Inc. said Tremfya guselkumab met the primary endpoint of improving PASI 90 response rate vs. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) in the Phase III ECLIPSE trial to treat moderate to severe...
18:25 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Sienna planning Phase III trials of pegcantratinib in psoriasis

Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) plans to start Phase III trials in 2H19 of pegcantratinib (SNA-120) to treat psoriasis despite reporting that the compound missed the primary endpoint in a Phase IIb trial to treat pruritus...
18:24 , Nov 9, 2018 |  BC Week In Review  |  Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Nov. 7 after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran...